$100M Series E: Insilico Medicine Raises (2025)
Key Facts
- Company
- Insilico Medicine
- Sector
- Healthcare AI
- Country
- United States
- Round Type
- Series E
- Investors
- WuXi AppTec, B Capital, Qiming Venture Partners
Funding Round Overview
Insilico Medicine announced a Series E round on February 1, 2025 totaling $100,000,000 led by WuXi AppTec. Insilico Medicine raised $100 million Series E for AI drug discovery. $100M Series E.
Deal Highlights
- Capital involved: $100,000,000.
- Round: Series E.
- Investors: WuXi AppTec, B Capital, Qiming Venture Partners.
Company and Sector Context
Insilico Medicine builds in the healthcare ai sector, one of the most active areas in AI investment today. Based in United States, the company is part of a global wave of startups scaling AI into production across regulated and enterprise environments.
How the Capital Helps
Disclosed details include $100M Series E. In healthcare ai, speed to market and access to high-quality talent often determine category leadership.
Competitive Landscape
Funding activity in healthcare ai continues to intensify as incumbents and startups race to ship reliable AI systems. This round signals ongoing investor confidence in differentiated technology and defensible distribution.
Looking Ahead
This funding positions Insilico Medicine for continued growth in the healthcare ai landscape. As AI adoption accelerates across industries, deals like this signal where capital and strategic attention are moving next.
News Sources
Frequently Asked Questions
How much did Insilico Medicine raise?
Insilico Medicine raised $100,000,000 in Series E announced on February 1, 2025.
Who invested in Insilico Medicine's Series E?
The investors in Insilico Medicine's Series E include WuXi AppTec, B Capital, Qiming Venture Partners.
What sector is Insilico Medicine in?
Insilico Medicine operates in the Healthcare AI sector and is based in United States.